Crinetics Pharmaceuticals (CRNX) Other Non Operating Income (2024 - 2026)

Crinetics Pharmaceuticals' Other Non Operating Income history runs 3 years deep, the most recent figure standing at -$131000.0 for Q1 2026.

• On a quarterly basis, Other Non Operating Income rose 35.47% year-over-year to -$131000.0 in Q1 2026; TTM through Mar 2026 was -$508000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$357000.0, up 31.21% from the prior year.
• Other Non Operating Income slipped to -$131000.0 in Q1 2026 per CRNX's latest filing, from -$125000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at -$37000.0 in Q3 2024 and bottomed at -$218000.0 in Q4 2024.
• The 3-year median for Other Non Operating Income is -$128000.0 (2025), against an average of -$127166.7.
• Biggest YoY gain for Other Non Operating Income was 42.66% in 2025; the steepest drop was 32.43% in 2025.
• Year by year, Other Non Operating Income stood at -$218000.0 in 2024, then jumped by 42.66% to -$125000.0 in 2025, then fell by 4.8% to -$131000.0 in 2026.
• Per Business Quant, the three latest CRNX Other Non Operating Income figures stand at -$131000.0 (Q1 2026), -$125000.0 (Q4 2025), and -$49000.0 (Q3 2025).